New Content  edit
Get The App!

Loading the player...
JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results - ASCO 2011
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
COMFORT-II, the second pivotal Phase III trial of the Janus kinase, or JAK inhibitor ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, or MF, when compared to best available therapy. The European study, called COMFORT-II showed treatment with ruxolitinib provided a statistically significant reduction in spleen size in patients with primary MF, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, when compared with best available therapy, administered at doses and schedules determined by the investigator. The safety profile of ruxolitinib was consistent with previous studies. Discussed at ASCO 2011.